Grad BSc - Paradigm Biopharmaceutica MD Founder
| PBIGF Stock | USD 0.17 0.01 4.76% |
Insider
Grad BSc is MD Founder of Paradigm Biopharmaceuticals Limited
| Age | 64 |
| Phone | 61 3 9629 5566 |
| Web | https://www.paradigmbiopharma.com |
Paradigm Biopharmaceutica Management Efficiency
The company has return on total asset (ROA) of (0.4422) % which means that it has lost $0.4422 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.651) %, meaning that it generated substantial loss on money invested by shareholders. Paradigm Biopharmaceutica's management efficiency ratios could be used to measure how well Paradigm Biopharmaceutica manages its routine affairs as well as how well it operates its assets and liabilities.Paradigm Biopharmaceuticals Limited has accumulated 616.67 K in total debt with debt to equity ratio (D/E) of 0.01, which may suggest the company is not taking enough advantage from borrowing. Paradigm Biopharmaceutica has a current ratio of 5.9, suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist Paradigm Biopharmaceutica until it has trouble settling it off, either with new capital or with free cash flow. So, Paradigm Biopharmaceutica's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Paradigm Biopharmaceutica sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Paradigm to invest in growth at high rates of return. When we think about Paradigm Biopharmaceutica's use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | INSIDER Age | ||
| Robert CFA | Satellos Bioscience | N/A | |
| Anthony Good | Imugene Limited | N/A | |
| PharmD MBA | Imugene Limited | N/A | |
| William Jarosz | Satellos Bioscience | 67 | |
| Jos MD | Shield Therapeutics plc | N/A | |
| CPA CMA | Satellos Bioscience | 71 | |
| Gregory Madison | Shield Therapeutics plc | 55 | |
| Ursula McCurry | Imugene Limited | N/A | |
| Lucy HuntingtonBailey | Shield Therapeutics plc | N/A | |
| Giovanni Selvaggi | Imugene Limited | N/A | |
| Dr BSc | Imugene Limited | N/A | |
| HansPeter Rudolf | Shield Therapeutics plc | N/A | |
| ACA BSc | Imugene Limited | 56 | |
| Suzanne Wood | Shield Therapeutics plc | N/A | |
| Francis MBA | Satellos Bioscience | 68 | |
| BA ASiA | Imugene Limited | 67 | |
| Michael Rudnicki | Satellos Bioscience | 62 | |
| Philip MA | Satellos Bioscience | 55 | |
| Nathan CA | Imugene Limited | N/A | |
| Carol Akinola | Shield Therapeutics plc | N/A | |
| Bsc BSc | Satellos Bioscience | 63 | |
Management Performance
| Return On Equity | -0.65 | |||
| Return On Asset | -0.44 |
Paradigm Biopharmaceutica Leadership Team
Elected by the shareholders, the Paradigm Biopharmaceutica's board of directors comprises two types of representatives: Paradigm Biopharmaceutica inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Paradigm. The board's role is to monitor Paradigm Biopharmaceutica's management team and ensure that shareholders' interests are well served. Paradigm Biopharmaceutica's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Paradigm Biopharmaceutica's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Grad BSc, MD Founder | ||
| Simon White, Director Relations | ||
| Michael Imperiale, Global MPS | ||
| MS MD, Chief Director | ||
| Ravi Krishnan, Chief Officer | ||
| Justin Cahill, Chief Officer | ||
| Mukesh Ahuja, Global OA | ||
| Beverley Huttmann, Commercial Head | ||
| Michelle Coffey, Global Affairs | ||
| Marco Polizzi, Ex Officer |
Paradigm Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Paradigm Biopharmaceutica a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.65 | |||
| Return On Asset | -0.44 | |||
| Operating Margin | (604.99) % | |||
| Current Valuation | 217 M | |||
| Shares Outstanding | 282.24 M | |||
| Shares Owned By Insiders | 16.46 % | |||
| Shares Owned By Institutions | 18.70 % | |||
| Price To Book | 8.76 X | |||
| Price To Sales | 3,287 X | |||
| Revenue | 79.22 K |
Currently Active Assets on Macroaxis
Other Information on Investing in Paradigm Pink Sheet
Paradigm Biopharmaceutica financial ratios help investors to determine whether Paradigm Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Paradigm with respect to the benefits of owning Paradigm Biopharmaceutica security.